AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

17."At eight years old, I got my period. Obviously concerned about how young I was, my mom took me to the doctor. The doctor ...

Roorkee have uncovered a crucial regulatory mechanism in Acinetobacter baumannii -- a highly drug-resistant superbug ...

The study, published in mBio, the journal of the American Society for Microbiology (ASM), reveals how the pathogen controls its attack and defense systems, paving the way for new treatment strategies.

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment ...

CAMBRIDGE, MA AND PITTSBURGH, PA / ACCESS Newswire / February 10, 2025 / Next Gen Diagnostics (NGD), a pioneer in the development of machine learning models for whole genome sequence- (WGS-) based det ...

I am not a doctor and the following information may not be 100% accurate but, to the best of my ability, the intention of ...

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...

The New Hampshire Department of Health and Human Services (DHHS) said a person from Merrimack County has become the first ...

An antibiotic used to treat infective diarrhea could be an effective drug for a type of inflammatory bowel disease, a new ...

An expert briefly describes the study ‘Single Dose Aminoglycosides versus Carbapenems for the Treatment of Uncomplicated ...